N/A N=30 Treatment

The Effect of Per Oral Immunotherapy in Severe Milk, Peanut and Egg Allergy in Adults

Food Allergy

Bottom Line

View on ClinicalTrials.gov: NCT03361072 ↗

Enrolled (actual)

Serious AEs

20.0%

Results posted

May 2025

Primary outcome: Primary: Desensitisation — 7; 5; 2 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Oral immunotherapy (Dietary_supplement)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Helsinki University Central Hospital
Primary completion: Mar 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Desensitisation	7; 5; 2	—
SECONDARY Worries Associated With Food Allergy	77.7; 69.7; 61.0; 79.00; 39.5; 25.0	—

Summary

The aim is to analyse the results of per oral immunotherapy treatment in severe milk, peanut or egg allergy in adults. This is the second part of the oral immunotherapy study in adults at Skin and Allergy Hospital. The diagnosis of food allergy is verified with positive history, skin prick tests, egg and milk allergen specific IgE (immunoglobulin E) antibodies. In addition, food allergy is verified with an open label (milk allergy) or blind (peanut and egg allergy) allergen specific challenge test. OIT (oral immunotherapy) is performed according to a detailed plan. Lung function parameters are followed before OIT and and a year after OIT.

Eligibility Criteria

Inclusion Criteria

severe milk, peanut or egg allergy verified with positive symptom history, skin prick tests and serum IgE tests and a challenge test

Exclusion Criteria

instable cerebrovascular or heart disease, active autoimmune disease or cancer, or current use of betablockers.
poorly controlled asthma or FEV1 < 70% (FEV1< -2SD)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03361072). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.